| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
105,890,000 |
| Market
Cap: |
2.40(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.87 - $26.1 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer therapies. Co.'s products include: Domvanalimab, which is an anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance; Etrumadenant, which is a dual A2a/A2b adenosine receptor antagonist, designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells; AB680, which is a potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to monoclonal antibodies; and Zimberelimab, which is Co.'s anti-PD-1 antibody that Co. in-licensed to enable the development of its combination regimens.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,403,436 |
16,641,531 |
| Total Buy Value |
$0 |
$0 |
$15,402,661 |
$335,402,656 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
3 |
4 |
| Total Shares Sold |
409,102 |
410,681 |
414,275 |
535,469 |
| Total Sell Value |
$8,267,185 |
$8,285,943 |
$8,339,853 |
$10,708,269 |
| Total People Sold |
7 |
7 |
7 |
7 |
| Total Sell Transactions |
27 |
28 |
29 |
39 |
| End Date |
2025-09-25 |
2025-06-24 |
2024-12-24 |
2023-12-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Azoy Alexander |
Chief Accounting Officer |
• – – |
2025-12-18 |
4 |
AS |
$22.25 |
$96,614 |
D/D |
(4,343) |
18,531 |
|
-0% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• – – |
2025-12-17 |
4 |
S |
$22.16 |
$221,218 |
D/D |
(9,983) |
193,024 |
|
1% |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2025-12-17 |
4 |
S |
$22.16 |
$150,906 |
D/D |
(6,810) |
124,734 |
|
1% |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2025-12-17 |
4 |
S |
$22.16 |
$132,071 |
D/D |
(5,960) |
74,476 |
|
1% |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2025-12-17 |
4 |
S |
$22.16 |
$570,474 |
D/D |
(25,744) |
2,194,809 |
|
1% |
|
| Azoy Alexander |
Chief Accounting Officer |
• – – |
2025-12-17 |
4 |
AS |
$22.16 |
$46,823 |
D/D |
(2,113) |
22,874 |
|
-1% |
|
| Jaen Juan C. |
President |
• – – |
2025-12-17 |
4 |
S |
$22.16 |
$221,218 |
D/D |
(9,983) |
346,012 |
|
1% |
|
| Markus Richard |
Chief Medical Officer |
• – – |
2025-12-17 |
4 |
S |
$22.16 |
$99,585 |
D/D |
(4,494) |
65,647 |
|
1% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• – – |
2025-12-16 |
4 |
S |
$21.88 |
$245,651 |
D/D |
(11,225) |
203,007 |
|
1% |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2025-12-16 |
4 |
S |
$21.88 |
$167,590 |
D/D |
(7,658) |
131,544 |
|
1% |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2025-12-16 |
4 |
S |
$21.88 |
$146,669 |
D/D |
(6,702) |
80,436 |
|
1% |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2025-12-16 |
4 |
S |
$21.88 |
$633,485 |
D/D |
(28,947) |
2,220,553 |
|
1% |
|
| Azoy Alexander |
Chief Accounting Officer |
• – – |
2025-12-16 |
4 |
AS |
$21.88 |
$51,997 |
D/D |
(2,376) |
24,987 |
|
-1% |
|
| Jaen Juan C. |
President |
• – – |
2025-12-16 |
4 |
S |
$21.88 |
$245,651 |
D/D |
(11,225) |
355,995 |
|
1% |
|
| Markus Richard |
Chief Medical Officer |
• – – |
2025-12-16 |
4 |
S |
$21.88 |
$110,559 |
D/D |
(5,052) |
70,141 |
|
1% |
|
| Azoy Alexander |
Chief Accounting Officer |
• – – |
2025-11-26 |
4 |
AS |
$26.00 |
$49,400 |
D/D |
(1,900) |
27,363 |
|
-14% |
|
| Azoy Alexander |
Chief Accounting Officer |
• – – |
2025-11-26 |
4 |
OE |
$13.33 |
$25,327 |
D/D |
1,900 |
29,263 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2025-11-26 |
4 |
AS |
$25.00 |
$125,000 |
D/D |
(5,000) |
87,138 |
|
-14% |
|
| Jaen Juan C. |
President |
• – – |
2025-11-18 |
4 |
AS |
$19.75 |
$99,738 |
I/I |
(5,050) |
1,037,060 |
|
9% |
|
| Jaen Juan C. |
President |
• – – |
2025-11-17 |
4 |
AS |
$20.23 |
$913,027 |
I/I |
(44,950) |
1,042,110 |
|
10% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• – – |
2025-11-07 |
4 |
AS |
$18.97 |
$954,066 |
D/D |
(50,291) |
214,232 |
|
14% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• – – |
2025-11-07 |
4 |
OE |
$1.23 |
$61,737 |
D/D |
50,291 |
264,523 |
|
- |
|
| Jaen Juan C. |
President |
• – – |
2025-10-30 |
4 |
AS |
$20.32 |
$87,650 |
I/I |
(4,314) |
1,087,060 |
|
9% |
|
| Jaen Juan C. |
President |
• – – |
2025-10-29 |
4 |
AS |
$20.49 |
$1,626,634 |
I/I |
(77,840) |
1,091,374 |
|
8% |
|
| Jaen Juan C. |
President |
• – – |
2025-10-28 |
4 |
AS |
$20.19 |
$383,944 |
I/I |
(19,019) |
1,169,214 |
|
11% |
|
280 Records found
|
|
Page 1 of 12 |
|
|
0.51 (2.2%) 
